Jubilant Ingrevia Q4 FY25 profit jumps 155% as expenses fall

Key takeaway

Jubilant Ingrevia Ltd reported a sharp year-on-year increase in consolidated net profit for Q4FY25, helped by a meaningful decline in total expenses. The company’s revenue and total income were marginally lower versus the same quarter last year, but management highlighted improved margins in Specialty Chemicals and Nutrition, supported by ongoing cost reduction efforts. Alongside the results, the board recommended a final dividend of 250% (₹2.5 per share on face value ₹1), taking the total dividend for FY25 to 500% (₹5.0 per share) including the interim dividend.

Q4FY25 financial performance at a glance

For the March 2025 quarter, revenue was reported at ₹1,051 crore compared with ₹1,074 crore in Q4FY24, a decline of 2.14% year-on-year. Total expenses declined to ₹958 crore from ₹1,033 crore in the year-ago quarter, a fall of 7.26%. Consolidated net profit rose to ₹74 crore from ₹29 crore, an increase of 155.17% year-on-year. Earnings per share (EPS) increased to ₹4.65 from ₹1.84, up 152.72%.

A separate regulatory filing figure in the provided text pegged total income at ₹1,059.62 crore in Q4FY25 versus ₹1,083.94 crore a year ago, while expenses were stated at ₹957.87 crore compared with ₹1,032.54 crore. The filing also reported net profit of ₹74.05 crore for the quarter.

Management commentary: margins and cost actions

The company said it saw “sustained growth in revenue and margins” in its Specialty Chemicals and Nutrition businesses. It also credited ongoing cost reduction efforts for lifting profitability in the quarter. Management stated the quarter’s EBITDA margin reached 14.7% and profit after tax increased by about 153% year-on-year.

While overall revenue was slightly lower year-on-year, the company attributed the decline mainly to lower revenue from its Chemical Intermediary business segment. In the same commentary, the company reported EBITDA of ₹155 crore for the quarter, reflecting a 54% rise year-on-year and a 5% sequential increase.

Revenue: slight decline, mix and segments in focus

The numbers presented in the text show that Q4FY25 revenue (₹1,051 crore) was lower than Q4FY24 (₹1,074 crore). Management pointed to stronger performance in Specialty Chemicals and Nutrition, while Chemical Intermediaries weighed on the consolidated top line year-on-year.

The text also referenced a claim that the company achieved its “highest ever EBITDA for specialty chemicals,” with 93% year-on-year growth, and that international revenue share increased to 45% with 47% year-on-year growth. These points were stated as highlights alongside the broader note that overall revenue was slightly lower compared to the previous year.

Expenses fall drives profit expansion

The most visible swing factor in the quarter was the reduction in total expenses. With expenses down to about ₹958 crore in Q4FY25 from about ₹1,033 crore in Q4FY24, the company reported a disproportionately higher increase in profit despite a modest drop in revenue and total income.

This pattern aligns with the company’s stated cost optimisation efforts and margin improvement. In practical terms, it indicates that operating leverage and cost control played a larger role than top-line growth in driving Q4FY25 profitability.

Dividend: final dividend recommended, FY25 total at ₹5 per share

Jubilant Ingrevia said its board recommended a final dividend of 250%, which translates to ₹2.5 per equity share of face value ₹1 for FY25. The company stated this would result in a cash outflow of ₹39.8 crore.

It also said it had already declared an interim dividend of 250% (₹2.5 per share). The total dividend for FY25 therefore works out to 500% (₹5.0 per share), with an aggregate cash outflow of ₹79.8 crore, as stated in the provided text.

Full-year FY25: income up, profit up

For FY25, the regulatory filing numbers in the text showed net profit rising to ₹251.17 crore from ₹182.89 crore in the preceding fiscal year. Total income for FY25 increased to ₹4,215.43 crore from ₹4,171.10 crore in FY24.

These full-year figures suggest that, despite quarter-to-quarter variability and segment-level weakness in Chemical Intermediaries, the company delivered higher annual income and improved profitability in FY25 compared with FY24.

Snapshot table: Q4 trend and latest quarter metrics

Note: The text also cited Q4FY25 total income of ₹1,059.62 crore and expenses of ₹957.87 crore in a regulatory filing, with net profit of ₹74.05 crore.

Market impact: what the numbers signal for investors

The quarter’s headline is the profit surge against a modest decline in revenue and total income. For investors, that combination typically directs attention to sustainability of cost savings and the profitability profile of the higher-margin segments referenced by management, especially Specialty Chemicals and Nutrition.

The dividend recommendation adds a shareholder-return element to the result. The company’s disclosed cash outflow of ₹79.8 crore for FY25 dividends (interim plus final) provides a quantified view of cash commitment tied to payouts.

What to watch next

The text included an operating update table that referenced Q1FY26 performance: total revenue of ₹1,038 crore, EBITDA of ₹153 crore, and profit after tax of ₹75 crore, with EBITDA margin at 15% and EPS around ₹4.7. These figures, as presented, indicate profitability levels broadly consistent with the Q4FY25 margin commentary.

Investors will likely track whether the Chemical Intermediaries segment continues to recover, as management described marginal recovery with quarter-on-quarter growth in a later update. Any further disclosures on segment performance, cost optimisation progress, and demand trends in Fine Chemicals and CDMO were highlighted in the text as operational drivers.

Conclusion

Jubilant Ingrevia’s Q4FY25 results showed profit growth driven primarily by lower expenses and improved margins, even as revenue and total income declined slightly year-on-year. The board’s final dividend recommendation, together with the interim dividend, takes the FY25 payout to ₹5 per share, with total cash outflow stated at ₹79.8 crore. The next set of updates, including segment recovery in Chemical Intermediaries and continued margin trajectory in Specialty Chemicals and Nutrition, will be important reference points in upcoming quarters.